Clinical trial
Examining the Long Term Safety, Efficacy, and Corticosteroid-sparing Effect of…
NCT00356408 · UCB Pharma, Industry · Completed
Key facts
| NCT number | NCT00356408 |
|---|---|
| Title | Examining the Long Term Safety, Efficacy, and Corticosteroid-sparing Effect of Certolizumab Pegol in Crohn's Disease |
| Official title | An Open-label, Multi-center Trial to Examine the Long Term Safety, Efficacy, and Corticosteroid-sparing Effect of Certolizumab Pegol in Patients With Moderate to Severe Crohn's Disease Previously Enrolled in C87059 (COSPAR I, NCT00349752). |
| Acronym | COSPAR II |
| Lead sponsor | UCB Pharma, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Crohn's Disease |
| Intervention type | Biological |
| Interventions | Certolizumab pegol |
| Enrollment | 106 |
| Start date | Jan 1, 2007 |
| Primary completion | Feb 1, 2010 |
| Completion | Feb 1, 2010 |
| First posted | Jul 26, 2006 |
| Last update posted | Aug 9, 2018 |
| Countries | Canada, Germany, United States |
At a glance
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: